Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 30,000 shares of the company’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $22.26, for a total value of $667,800.00. Following the sale, the director now directly owns 514,581 shares of the company’s stock, valued at $11,454,573.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Entellus Medical Inc. (NASDAQ:ENTL) opened at 21.05 on Monday. The stock’s 50 day moving average price is $19.89 and its 200-day moving average price is $18.07. Entellus Medical Inc. has a one year low of $13.72 and a one year high of $22.57. The firm’s market cap is $396.77 million.

Entellus Medical (NASDAQ:ENTL) last released its earnings results on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.08. Entellus Medical had a negative return on equity of 41.83% and a negative net margin of 33.54%. The business had revenue of $18.73 million for the quarter, compared to analyst estimates of $18.48 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. Entellus Medical’s revenue was up 23.3% on a year-over-year basis. Analysts forecast that Entellus Medical Inc. will post ($1.23) earnings per share for the current year.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Several equities research analysts have recently commented on the company. BTIG Research reaffirmed a “buy” rating on shares of Entellus Medical in a report on Wednesday, June 29th. Zacks Investment Research raised Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Monday, August 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $23.00 target price on shares of Entellus Medical in a report on Friday, August 5th. Deutsche Bank AG assumed coverage on Entellus Medical in a report on Thursday. They set a “buy” rating and a $26.00 target price for the company. Finally, Bank of America Corp. reaffirmed a “buy” rating on shares of Entellus Medical in a report on Monday, July 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.75.

A number of hedge funds have recently added to or reduced their stakes in the company. Murphy Michael R raised its stake in Entellus Medical by 30.1% in the second quarter. Murphy Michael R now owns 627,441 shares of the medical technology company’s stock valued at $11,463,000 after buying an additional 145,304 shares during the last quarter. Cortina Asset Management LLC raised its stake in Entellus Medical by 39.2% in the second quarter. Cortina Asset Management LLC now owns 421,897 shares of the medical technology company’s stock valued at $7,708,000 after buying an additional 118,745 shares during the last quarter. Vanguard Group Inc. raised its stake in Entellus Medical by 5.1% in the second quarter. Vanguard Group Inc. now owns 215,395 shares of the medical technology company’s stock valued at $3,936,000 after buying an additional 10,532 shares during the last quarter. BlackRock Fund Advisors raised its stake in Entellus Medical by 40.1% in the second quarter. BlackRock Fund Advisors now owns 195,518 shares of the medical technology company’s stock valued at $3,572,000 after buying an additional 55,996 shares during the last quarter. Finally, Ghost Tree Capital LLC increased its position in shares of Entellus Medical by 9.1% in the second quarter. Ghost Tree Capital LLC now owns 120,000 shares of the medical technology company’s stock worth $2,192,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 66.22% of the company’s stock.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

5 Day Chart for NASDAQ:ENTL

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.